India has emerged as one among the top two sourcing hubs for the global pharmaceutical industry along with China, if the trends at CPhI Worldwide – the largest global pharmaceutical ingredients meet – are any indication.

The Indian contingent constituted more than a third of the total 22,000-plus visitors and 1,900-plus exhibitors to this three-day annual event at the Rho Fiera exhibition centre in Milan, Italy, last week.

According to sources with CMP, which organised the event, this is one of the largest ever participation by the Indian industry in the more than a decade-old history of CPhI.

India is the fourth largest manufacturer of pharmaceutical products in the world and the 12th largest in value terms. India could emerge as the second largest producer of active pharmaceutical ingredients (API), next to China, within two to five years, overtaking Italy, according to various estimates.

CPhI Worldwide is the key meeting place of pharmaceutical producers and buyers from different parts of the world, for new businesses and renewing supply contracts.

"India's problem was marketing. Though many were producing good pharmaceutical products. The trend which I see this year is the aggression of Indian companies to impress clients with quality presentations and professional approach," said a top professional with Codexis, USA.

Except for Cipla and Torrent, nearly all of India's leading drug makers exhibited their products at the event, with 40 top-level executives canvasing business. While Dr Reddy's team had about 45 people, the Ranbaxy contingent numbered 25, one of the largest groups at CPhI.

Other major Indian companies, which brought large teams for the event were Aurobindo, Dishman, Zydus Cadila, Orchid, Shasun, Sun Pharma, Wockhardt and Lupin. Even upcoming Indian API producer Arch Pharmalabs had a 15-member team with two stalls to display products.

Mr. Rakesh Joshi

Joshi Enterprise

Manager, Joshi Enterprise
Dispur, India

Free Member, Joined :02/02/2007
No of Topics Posted : 122
Reply/Comments : 16